Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling

The variable response to warfarin treatment often has a genetic basis. A protein homology model of human vitamin K epoxide reductase, subunit 1 (VKORC1), was generated to elucidate the mechanism of warfarin resistance observed in a patient with the Val66Met mutation. The VKORC1 homology model comprises four transmembrane (TM) helical domains and a half helical lid domain. Cys132 and Cys135, located in the N-terminal end of TM-4, are linked through a disulfide bond. Two distinct binding sites for warfarin were identified. Site-1, which binds vitamin K epoxide (KO) in a catalytically favorable orientation, shows higher affinity for S-warfarin compared with R-warfarin. Site-2, positioned in the domain occupied by the hydrophobic tail of KO, binds both warfarin enantiomers with similar affinity. Displacement of Arg37 occurs in the Val66Met mutant, blocking access of warfarin (but not KO) to Site-1, consistent with clinical observation of warfarin resistance.

[1]  Duan Li,et al.  On Restart Procedures for the Conjugate Gradient Method , 2004, Numerical Algorithms.

[2]  A. Somogyi,et al.  The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype. , 2013, British journal of clinical pharmacology.

[3]  M. Shearer,et al.  Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1 , 2004, Thrombosis and Haemostasis.

[4]  Sean R. Eddy,et al.  Profile hidden Markov models , 1998, Bioinform..

[5]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[6]  M. Shearer,et al.  Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1 , 2008, Journal of thrombosis and haemostasis : JTH.

[7]  A. Rettie,et al.  Pharmacogenomics of 4-hydroxycoumarin anticoagulants. , 2008, Drug metabolism reviews.

[8]  C. Ponting,et al.  Vitamin K epoxide reductase: homology, active site and catalytic mechanism. , 2004, Trends in biochemical sciences.

[9]  Jeffrey P. Jones,et al.  Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. , 2005, Annual review of pharmacology and toxicology.

[10]  T. Rapoport,et al.  Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners , 2010, Proceedings of the National Academy of Sciences.

[11]  Andreas Fregin,et al.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.

[12]  R. Russell,et al.  Amino‐Acid Properties and Consequences of Substitutions , 2003 .

[13]  J. Halperin,et al.  CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. , 2009, Pharmacogenomics.

[14]  Ajay N. Jain,et al.  Parameter estimation for scoring protein-ligand interactions using negative training data. , 2006, Journal of medicinal chemistry.

[15]  M. J. D. Powell,et al.  Restart procedures for the conjugate gradient method , 1977, Math. Program..

[16]  J. Miners,et al.  Application of Homology Modeling to Generate CYP1A1 Mutants with Enhanced Activation of the Cancer Chemotherapeutic Prodrug Dacarbazine , 2011, Molecular Pharmacology.

[17]  J. Oldenburg,et al.  The Genetic Basis of Resistance to Anticoagulants in Rodents , 2005, Genetics.

[18]  C. Deane,et al.  CODA: A combined algorithm for predicting the structurally variable regions of protein models , 2001, Protein science : a publication of the Protein Society.

[19]  M. Whirl‐Carrillo,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing , 2011, Clinical pharmacology and therapeutics.

[20]  A. Breckenridge,et al.  Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man , 1974, Clinical pharmacology and therapy.

[21]  Leonardo Pardo,et al.  Relation between sequence and structure in membrane proteins , 2013, Bioinform..

[22]  Gunnar von Heijne,et al.  Membrane Topology Mapping of Vitamin K Epoxide Reductase by in Vitro Translation/Cotranslocation* , 2005, Journal of Biological Chemistry.

[23]  M. Ozelo,et al.  VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy. , 2010, Thrombosis research.

[24]  J. Miners,et al.  The glycosidation of xenobiotics and endogenous compounds: versatility and redundancy in the UDP glycosyltransferase superfamily. , 2012, Pharmacology & therapeutics.

[25]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[26]  J. Miners,et al.  Identification of Residues That Confer Sugar Selectivity to UDP-Glycosyltransferase 3A (UGT3A) Enzymes* , 2012, The Journal of Biological Chemistry.

[27]  J. Miners,et al.  Interaction of sulphinpyrazone with warfarin , 2004, European Journal of Clinical Pharmacology.

[28]  A. Biswas,et al.  Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces. , 2013, Blood.

[29]  T. Rapoport,et al.  Structure of a bacterial homolog of vitamin K epoxide reductase , 2010, Nature.

[30]  C. Müller,et al.  Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment , 2011, Journal of thrombosis and haemostasis : JTH.

[31]  J. Miners,et al.  Comparative homology modeling of human cytochrome P4501A1 (CYP1A1) and confirmation of residues involved in 7-ethoxyresorufin O-deethylation by site-directed mutagenesis and enzyme kinetic analysis. , 2007, Archives of biochemistry and biophysics.